MarketCapExport financials
Achieve Life Sciences (ACHV)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Achieve Life Sciences Income Statement 2025-2008 | ACHV
Brief overview of profit and loss at Achieve Life Sciences
The comparison covers a five-year financial horizon. Achieve Life Sciences reported revenue of $5.5 million in 2011 and $5.1 million by 2016. The total change was −7.9%, with a CAGR of approximately −1.6%. The scale of the core business was largely unchanged.
The operating result measured by EBITDA moved from −$22.2 million to −$18.5 million, or +16.8%. Additional revenue translated efficiently into EBITDA. Comparing the endpoints gives EBITDA margins of −404.1% and −364.9%. The business generated more EBITDA from each unit of revenue.
The final result was −$14.7 million initially and −$20.1 million in the final year. The loss widened and increased the financial risk.
The market value of the business moved from 135 million dollars to 16.2 million dollars, or −88%. The valuation did not keep pace with the reported progress.
Financial takeaway
The indicators point to a weaker financial profile. The strongest signals are an improving EBITDA margin. Caution is warranted because of declining net profitability, a softer top-line trend and a low EBITDA margin. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Achieve Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
126 M | 93 M | 90.2 M | 48.2 M | 63.2 M | 22 M | 4.37 M | 4.25 M | 7.62 M | 16.2 M | 17.3 M | 36.4 M | 161 M | 180 M | 135 M | 223 B | - | - |
Shares |
43.6 M | 32.1 M | 19.8 M | 10.6 M | 8.12 M | 2.72 M | 412 K | 176 K | 24 K | 13.6 K | 11.9 K | 8.23 K | 6.67 K | 6.15 K | 4.42 K | 7.03 M | - | - |
Historical Prices |
2.9 | 2.9 | 4.55 | 4.55 | 7.78 | 8.1 | 10.6 | 24.2 | 268 | 1.1 K | 2.66 K | 5.04 K | 18.3 K | 28.9 K | 25.8 K | 31.7 K | 41.5 K | 13.9 K |
Net Income |
-54.6 M | -39.8 M | -29.8 M | -42.4 M | -33.2 M | -14.7 M | -16.4 M | -12.7 M | -10.6 M | -20.1 M | -16.8 M | -26.2 M | -31.8 M | -21.1 M | -14.7 M | -12.6 M | -5.48 M | - |
Revenue |
- | - | - | - | - | - | - | - | - | 5.06 M | 18.2 M | 27.1 M | 29.9 M | 20.1 M | 5.5 M | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | 18.2 M | 27.1 M | 29.9 M | 20.1 M | 5.5 M | - | - | - |
Interest Expense |
-36 K | -30 K | 2.85 M | 1.79 M | -75 K | -49 K | -37 K | -45 K | -35 K | -24 K | -64 K | -19 K | 120 K | 138 K | 6 K | 6 K | 70 K | - |
EBITDA |
228 K | 229 K | 228 K | 236 K | 250 K | 255 K | 31 K | 60 K | 838 K | -18.5 M | -18.5 M | -29.5 M | -35.1 M | -27.5 M | -22.2 M | 52 K | 50 K | - |
Operating Expenses |
- | - | - | - | - | - | 16.5 M | 12.8 M | 6.63 M | 23.7 M | 36.9 M | 56.8 M | 65.2 M | 47.7 M | 27.8 M | - | - | - |
General and Administrative Expenses |
- | 16.3 M | 11.4 M | 10.7 M | 9.13 M | 7.87 M | 6.85 M | 6.94 M | 3.53 M | 8.93 M | 11.8 M | 10.6 M | 9.89 M | 7.79 M | - | 5.84 M | 3.96 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Achieve Life Sciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
105 M | 93.5 M | 53.4 M | 3.41 M | 51 M | 34.7 M | 34.7 M | 819 K | 34.4 M | 34.3 M | 25 M | 451 K | 21.1 M | 19 M | 17.9 M | 992 K | 9.69 M | 9.65 M | 9.46 M | 449 K | 9.45 M | 7.39 M | 6.13 M | 522 K | 3.29 M | 1.74 M | 1.55 M | 1.47 M | 405 K | 359 K | 6.72 M | -2.27 M | 4.53 M | 1.53 M | 1.24 M | 1.19 M | 723 K | 2.12 K | 21.2 M | 21.2 K | 21.2 K | 29.9 M | 29.8 M | 29.8 M | 28.5 M | 23.5 M | 22.7 M | 1.15 M | 21.1 M | 15 M | 14.7 M | 8.14 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.6 M | 14.7 M | 14.7 M | 9.75 M | 9.74 M | 9.72 M | 9.75 M |
Net Income |
-12.1 M | -74.8 M | -10.2 M | -14.7 M | -14.4 M | -12.7 M | -12.8 M | -12.4 M | -12.5 M | -8.46 M | -6.49 M | -5.48 M | -7.11 M | -8.24 M | -8.99 M | -11.2 M | -13.1 M | -10.5 M | -7.57 M | -7.15 M | -6.69 M | -11.3 M | -8 M | -4.72 M | -3.76 M | -2.92 M | -3.32 M | -3.19 M | -3.67 M | -3.62 M | -5.9 M | -3.64 M | -3.24 M | -2.79 M | -3.02 M | -3.74 M | -6.47 M | -169 K | -205 K | -486 K | -268 K | -238 K | -242 K | -1.72 M | -4.55 M | -6.01 M | -4.52 M | -5.68 M | -4.91 M | -7.02 M | -8.64 M | -6.68 M | -10.1 M | -8.42 M | -6.7 M | -4.1 M | -5.92 M | -4.22 M | -6.86 M | -9.57 M | 4.47 M | -6.53 M | -3.04 M |
Operating Income |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.29 M | 5.94 M | -5.5 M | - | 4.1 M | 4.99 M | -5.22 M |
Interest Expense |
-16 K | -5 K | -13 K | 7 K | -5 K | -59 K | 21 K | -5 K | -8 K | -2 K | -15 K | 17 K | -17 K | -6 K | -3 K | 59 K | -30 K | 5 K | 6 K | -39 K | -1 K | -12 K | -23 K | -25 K | -12 K | -7 K | -5 K | - | 4 K | -3 K | -26 K | -11 K | -7 K | -9 K | -18 K | - | -7 K | -11 K | -8 K | - | -7 K | -35 K | 10 K | - | -14 K | -7 K | -39 K | -5 K | -11 K | -4 K | 2 K | -1 K | -11 K | 36 K | 96 K | - | -24 K | -6 K | 23 K | -16 K | -62 K | 87 K | -4 K |
EBITDA |
- | 15 K | 100 K | - | 100 K | 100 K | 100 K | - | 100 K | 100 K | - | - | 100 K | 100 K | 100 K | - | 100 K | 100 K | 100 K | - | 100 K | 100 K | 100 K | - | 100 K | 100 K | 100 K | - | 192 K | 100 K | 65 K | - | 100 K | 100 K | 100 K | - | 191 K | 100 K | 100 K | - | 166 K | 103 K | 56 K | - | 178 K | 116 K | 46 K | 58 K | 55 K | 55 K | 55 K | 65 K | 62 K | 56 K | 44 K | - | 8.36 M | 5.99 M | -5.48 M | - | 4.12 M | 5.03 M | -5.21 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.37 M | - | 11.4 M | - | 6.37 M | 12.3 M | 12 M | - | - | - | - | - | - | - | - | - | - | - | -4.1 M | -4.99 M | - |
General and Administrative Expenses |
- | - | - | - | 9.37 M | 5.86 M | 5.8 M | 4.89 M | 4.86 M | 3.32 M | 3.18 M | 2.27 M | 2.99 M | 3.13 M | 3.04 M | 2.25 M | 2.77 M | 2.87 M | 2.84 M | 2.61 M | 2.1 M | 2.08 M | 2.34 M | 2.37 M | 1.86 M | 1.82 M | 1.82 M | 1.45 M | 1.89 M | 1.63 M | 1.88 M | 1.63 M | 1.75 M | 1.75 M | 1.81 M | 1.63 M | 1.55 M | 96 K | 260 K | 529 K | 329 K | 281 K | 289 K | 2.92 M | 3.12 M | 3.07 M | 2.7 M | 2.73 M | 2.46 M | 2.68 M | 2.76 M | 2.45 M | 2.47 M | 2.47 M | 2.5 M | 2.04 M | 1.96 M | 2.05 M | 1.74 M | 1.73 M | 1.46 M | 1.47 M | 1.57 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Achieve Life Sciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Britain
Danmark
Australia
Cayman-islands
Israel
Canada
France
Irlanda
